The insider trader inquiry at the US Food and Drug Administration is expanding, reports the Wall Street Journal. In March, chemist Cheng Yi Liang and his son Andrew, who did not work at FDA, were charged with trading drug company stock in advance of agency decisions. The Department of Justice is now seeking information from another FDA scientist who has not been named, nor charged with anything.